文献速递肥胖与代谢综合征

青少年肥胖与中年癌症风险:以色列230万青少年人群队列研究

Adolescent obesity and midlife cancer risk: a population-based cohort study of 2·3 million adolescents in Israel.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-02-03

该全国性人群队列纳入1967至2010年接受预招募强制体检的2298130名青少年,按美国CDC百分位分类17岁时BMI,随访至2012年12月31日记录癌症发病、至2017年12月31日记录癌症患者全因死亡。男性青少年肥胖者调整HR为1.26(95%CI 1.18-1.35);女性肥胖与总体癌症无关联,排除宫颈癌和乳腺癌后调整HR为1.27(1.13-1.44)。高BMI(≥85百分位)与10年后癌症风险升高相关。

要点

  • 男性青少年肥胖者癌症发病调整HR为1.26(95%CI 1.18-1.35)。
  • 女性青少年肥胖与总体癌症无关联,排除宫颈癌和乳腺癌后调整HR为1.27(1.13-1.44)。
  • 男女高BMI(≥85百分位)与10年后癌症风险升高相关,且队列后期该关联较早期更明显。

核心结论

  • 青少年肥胖患病率上升及青少年BMI与癌症发病的可能关联,可能增加未来肥胖相关癌症负担。
  • 作者认为青少年BMI可构成癌症预防的重要干预靶点。

研究设计与样本

  • 全国性、人群为基础的青少年队列,1967至2010年预招募强制体检时测量身高体重,按美国CDC百分位分类BMI。
  • 采用Cox比例风险模型估计癌症发病的HR和95%CI,以第5-49百分位BMI组为参照。
  • 主要结局为1967年1月1日至2012年12月31日以色列国家癌症登记记录的任一癌症诊断,基线已诊断癌症者排除。
  • 次要结局为1967年1月1日至2017年12月31日队列中癌症患者的全因死亡。

主要发现

  • 男性随访29542735人年记录26353例癌症发病,女性随访18044863人年记录29488例癌症发病。
  • 癌症发病率随BMI百分位逐渐升高。
  • 男性青少年肥胖者调整HR为1.26(95%CI 1.18-1.35)。
  • 女性肥胖与总体癌症无关联,排除宫颈癌和乳腺癌后女性青少年肥胖者调整HR为1.27(95%CI 1.13-1.44)。
  • 男女高BMI(≥85百分位)与10年后癌症风险升高相关,且队列后期该关联较早期更明显;BMI与死亡风险升高正相关。

关键数值与推荐

  • 高BMI的预计人群归因风险男性为5.1%(95%CI 4.2-6.1),女性为5.7%(95%CI 4.2-7.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity has been established as a causal factor for several types of cancer, and adolescent obesity is increasing worldwide. We examined associations between measured body-mass index (BMI) at age 17 years and cancer incidence, and with mortality among those who developed cancer. METHODS: In a nationwide, population-based cohort of adolescents, height and weight were measured at pre-recruitment mandatory medical examination during 1967-2010. BMI was classified according to US Center for Disease Control and Prevention percentiles. We applied Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% CIs for incident cases of cancer using the 5th-49th BMI percentile group as a reference. The primary outcome was any cancer diagnosis between Jan 1, 1967, and Dec 31, 2012, as recorded in the Israeli National Cancer Registry. Participants with a diagnosis of cancer at baseline (before military recruitment assessment) were excluded from this analysis. The secondary outcome of this study was all-cause mortality among cohort members who had cancer, between Jan 1, 1967, and Dec 31, 2017. FINDINGS: Of the 2 458 170 participants examined between Jan 1, 1967, and Dec 31, 2010, 160 040 were excluded. 2 298 130 participants of which 928 110 were women and 1 370 020 were men. During 29 542 735 person-years of follow-up in men, 26 353 incident cases of cancer were recorded and in 18 044 863 person-years of follow-up in women, 29 488 incident cases of cancer were recorded. Cancer incidence increased gradually across BMI percentiles. The adjusted HR was 1·26 (95% CI 1·18-1·35) among men with adolescent obesity. Among women, we found no association between obesity and overall cancer, driven by inverse associations of obesity with cervical and breast cancers. When these cancers were excluded, the adjusted HR for cancer was 1·27 (1·13-1·44) among women with adolescent obesity. In both sexes, high BMI (≥85th percentile) was associated with an increased cancer risk after 10 years. This association was accentuated in the late period of the cohort versus the early period of the cohort. BMI was positively associated with a higher risk of mortality. The projected population attributable risk for high BMI was 5·1% (4·2-6·1) for men and 5·7% (4·2-7·3) for women. INTERPRETATION: The increasing prevalence of adolescent obesity and the possible association between adolescent BMI and cancer incidence might increase the future burden of obesity-related cancers. BMI among adolescents could constitute an important intervention target for cancer prevention. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Furer A, Afek A, Sommer A, et al. Adolescent obesity and midlife cancer risk: a population-based cohort study of 2·3 million adolescents in Israel. Lancet Diabetes Endocrinol. 2020. PMID: 32027851. doi:10.1016/S2213-8587(20)30019-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。